Users Coming Off Slimming Jabs Regain Weight Far More Rapidly Than Those on Conventional Diets

A recent study indicates that people who discontinue new weight-loss injections like Mounjaro or Wegovy can put back on reduced body mass far faster than those who end conventional diet and exercise regimens.

Findings released in a major health publication shows that while obese people often shed a large proportion of their total mass while on the medication, the weight is regained at an estimated rate of nearly a kilo each month upon discontinuation.

"Users using such drugs should be informed of the risk of rapid rebound weight gain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.

This pace of recovery suggests a reversion to original mass within about a year and a half.

Analyzing Treatments

The research, which examined dozens of studies involving over 9,000 of participants, contrasted the outcomes of these new drugs with other pills.

The team emphasize that people who shed pounds through lifestyle changes alone usually experience a slower creep back—perhaps 0.1 kg a month—once they finish.

Explaining the Rapid Rebound

Experts believe the way of the jabs accounts for the accelerated weight return.

These medications copy a natural hormone called glucagon-like peptide-1, which controls hunger.

"Long-term administration of the hormone concentrations several times higher than normal might result in the body to generate a reduced amount of its own natural GLP-1, and could reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.

"Withdrawal of this medication results in hunger is no longer kept in check, making binge eating far more likely."

A Chronic Condition?

Health authorities advise the injections for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.

A number of clinicians argue that, given the significant potential of relapse, the therapy should be considered long-term.

This view is reinforced by drug manufacturers, who say that the results "underscore the chronic character of obesity," akin to managing conditions like hypertension.

Patient Testimonies

People who have come off the medication report a powerful resurgence of appetite.

"I experienced a switch flipping and I was suddenly starving," said an individual.

The struggle is compounded if patients have not established sustainable dietary or behavioural changes during therapy.

Widespread Interest

Recent estimates show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.

• Adoption is greater among females than men.
• The middle-aged age group shows the highest usage rates.
• A large proportion access the medications through private healthcare rather than public health services.

In conclusion, clinicians caution that while GLP-1 drugs are effective agents for weight loss, they are not a magic cure and lasting health benefits relies on ongoing lifestyle support.